'''Aptiganel''' ('''Cerestat'''; '''CNS-1102''') is an unsuccessful drug candidate which acts as a noncompetitive [[NMDA antagonist]], and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke.<ref>Reddy NL, Hu LY, Cotter RE, Fischer JB, Wong WJ, McBurney RN, Weber E, Holmes DL, Wong ST, Prasad R, et al. Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist. ''Journal of Medicinal Chemistry''. 1994 Jan 21;37(2):260-7. {{PMID|8295213}}</ref> It has [[neuroprotective]] effects and was researched for potential use in the treatment of [[stroke]],<ref>Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. ''British Journal of Clinical Pharmacology''. 1994 Jul;38(1):33-8. {{PMID|7946934}}</ref> but despite positive results in animal studies,<ref>Sch√§bitz WR, Li F, Fisher M. The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. ''Stroke''. 2000 Jul;31(7):1709-14. {{PMID|10884477}}</ref> human trials showed limited efficacy,<ref>Albers GW, Goldstein LB, Hall D, Lesko LM; Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. ''Journal of the American Medical Association''. 2001 Dec 5;286(21):2673-82. {{PMID|11730442}}</ref> as well as undesirable side effects such as [[sedation]] and [[hallucinations]],<ref>Muir KW, Grosset DG, Lees KR. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. ''Clinical Neuropharmacology''. 1997 Aug;20(4):311-21. {{PMID|9260729}}</ref><ref>Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. ''Neurology''. 1997 Nov;49(5 Suppl 4):S66-9. {{PMID|9371155}}</ref> and clinical development was ultimately not continued.<ref>Hoyte L, Barber PA, Buchan AM, Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. ''Current Molecular Medicine''. 2004 Mar;4(2):131-6. {{PMID|15032709}}</ref>  
